{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:11:44Z","timestamp":1793225504265,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.anai.2025.02.026","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:20:21Z","timestamp":1741468821000},"page":"630-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gene therapy for inborn errors of immunity"],"prefix":"10.1016","volume":"134","author":[{"given":"Sathi","family":"Wijeyesinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-3697","authenticated-orcid":false,"given":"Javier","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2025.02.026_bib0001","unstructured":"International Union of Immunological Societies. Human inborn errors of immunity committee (IEI). Accessed January 20, 2025. Available at: https:\/\/iuis.org\/committees\/iei"},{"issue":"6","key":"10.1016\/j.anai.2025.02.026_bib0002","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaci.2024.01.011","article-title":"Validating inborn errors of immunity prevalence and risk with nationally representative electronic health data","volume":"153","author":"Rider","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"7583","key":"10.1016\/j.anai.2025.02.026_bib0003","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"issue":"10396","key":"10.1016\/j.anai.2025.02.026_bib0004","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","article-title":"Measuring the effect of newborn screening on survival after hematopoietic stem cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium","volume":"402","author":"Thakar","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaci.2023.09.027","article-title":"Posttransplantation late complications increase over time for patients with SCID: a Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study","volume":"153","author":"Eissa","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5977","key":"10.1016\/j.anai.2025.02.026_bib0006","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature"},{"issue":"5235","key":"10.1016\/j.anai.2025.02.026_bib0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"5235","key":"10.1016\/j.anai.2025.02.026_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.anai.2025.02.026_bib0009","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"issue":"5577","key":"10.1016\/j.anai.2025.02.026_bib0010","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"issue":"8041","key":"10.1016\/j.anai.2025.02.026_bib0011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-024-08250-x","article-title":"Lon-term lineage commitment in hematopoietic stem cell gene therapy","volume":"636","author":"Calabria","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/imr.13305","article-title":"Gene regulation in inborn errors of immunity: implications for gene therapy design and efficacy","volume":"322","author":"Ghanim","year":"2024","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.anai.2025.02.026_bib0013","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jaip.2024.01.019","article-title":"What a clinician needs to know about genome editing: status and opportunities for inborn errors of immunity","volume":"12","author":"Mudde","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.02.026_bib0014","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaip.2023.01.032","article-title":"Updated management guidelines for adenosine deaminase deficiency","volume":"11","author":"Grunebaum","year":"2023","journal-title":"J Allergy Clin Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.02.026_bib0015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jaip.2023.01.028","article-title":"Long-term immune reconstitution in ADA deficient patients treated with elapegademase: a real world experience","volume":"11","author":"Murguia-Favela","year":"2023","journal-title":"J Allergy Clin Pract"},{"issue":"7","key":"10.1016\/j.anai.2025.02.026_bib0016","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2022016196","article-title":"Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC","volume":"140","author":"Cuvelier","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/mthe.2002.0535","article-title":"Adenosine deaminase gene therapy protocol revisited","volume":"5","author":"Kohn","year":"2002","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2016.29010.ind","article-title":"Investor outlook: rising from the ashes; GSK's European approval of Strimvelis for ADA-SCID","volume":"27","author":"Schimmer","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"0","key":"10.1016\/j.anai.2025.02.026_bib0019","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","article-title":"Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency","volume":"3","author":"Migliavacca","year":"2024","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.anai.2025.02.026_bib0020","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2020010260","article-title":"Lon-term outcomes after gene therapy for adenosine deaminase severe combined immunodeficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.anai.2025.02.026_bib0021","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/gt.2009.127","article-title":"Progress and prospects: gene therapy for inherited immunodeficiencies","volume":"16","author":"Qaim","year":"2009","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0022","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-024-47866-5","article-title":"A case of T cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID","volume":"15","author":"Cesana","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.anai.2025.02.026_bib0023","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ymthe.2006.03.001","article-title":"Genotoxicity of retroviral integration in hematopoietic cells","volume":"13","author":"Nienhuis","year":"2006","journal-title":"Mol Ther"},{"issue":"21","key":"10.1016\/j.anai.2025.02.026_bib0024","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.02.026_bib0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2024-202543","article-title":"Ex vivo hematopoietic stem cell (HSC) gene therapy may represent a curative life-threatening inborn error of immunity severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID)","volume":"144","author":"Masiuk","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2018.08.027","article-title":"The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)","volume":"143","author":"Dvorak","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"9452","key":"10.1016\/j.anai.2025.02.026_bib0027","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy for X-linked severe combined immunodeficiency by used of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.anai.2025.02.026_bib0028","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified g-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Eng J Med"},{"issue":"40","key":"10.1016\/j.anai.2025.02.026_bib0029","doi-asserted-by":"crossref","first-page":"eadg9959","DOI":"10.1126\/sciadv.adg9959","article-title":"Integrome signatures of lentiviral gene therapy for SCID-X1 patients","volume":"9","author":"Yan","year":"2023","journal-title":"Sci Adv"},{"issue":"335","key":"10.1016\/j.anai.2025.02.026_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.anai.2025.02.026_bib0031","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0032","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41467-022-31344-x","article-title":"Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency","volume":"13","author":"De Ravin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.anai.2025.02.026_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1067417","article-title":"CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells","volume":"13","author":"Brault","year":"2023","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.anai.2025.02.026_bib0034","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month post-transplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.anai.2025.02.026_bib0035","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for Artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.02.026_bib0036","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood-2024-208350","article-title":"Gene therapy for Artemis-SCID and Artemis-leaky-SCID patients: preliminary results of the French Artegene Phase I\/II clinical trial","volume":"144","author":"Diana","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anai.2025.02.026_bib0037","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10875-018-0537-4","article-title":"RAG deficiency: two genes, many diseases","volume":"38","author":"Delmonte","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.anai.2025.02.026_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106931","article-title":"Gene therapy strategies for RAG1 deficiency: challenges and breakthroughs","volume":"270","author":"Gilioli","year":"2024","journal-title":"Immunol Lett"},{"issue":"4","key":"10.1016\/j.anai.2025.02.026_bib0039","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome","volume":"133","author":"Van TiL","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.02.026_bib0040","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/bloodadvances.2023011766","article-title":"Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency","volume":"8","author":"Pavel-Dinu","year":"2024","journal-title":"Blood Adv"},{"issue":"733","key":"10.1016\/j.anai.2025.02.026_bib0041","doi-asserted-by":"crossref","first-page":"eadh8162","DOI":"10.1126\/scitranslmed.adh8162","article-title":"Exonic knockout and knockin gene editing in hematopoietic stem and progenitor cells rescues RAG1 immunodeficiency","volume":"16","author":"Castiello","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0042","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1038\/s41467-023-42036-5","article-title":"CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"issue":"17-18","key":"10.1016\/j.anai.2025.02.026_bib0043","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/hum.2024.103","article-title":"Alpharetroviral vector-mediated gene therapy for IL7RA-deficient severe combined immunodeficiency","volume":"35","author":"Ha","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"7-8","key":"10.1016\/j.anai.2025.02.026_bib0044","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/hum.2023.100","article-title":"CRISPR\/Cas9-based disease modeling and functional correction of interleukin 7 receptor alpha severe combined immunodeficiency in T-lymphocytes and hematopoietic stem cells","volume":"35","author":"Rai","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.anai.2025.02.026_bib0045","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cell.2023.02.027","article-title":"Human T cell generation is restored in CD3\u03b4 severe combined immunodeficiency through adenine base editing","volume":"186","author":"McAuley","year":"2023","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.anai.2025.02.026_bib0046","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood.2021014687","article-title":"Hematopietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis","volume":"139","author":"Albert","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.anai.2025.02.026_bib0047","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2014","journal-title":"N Eng J Med"},{"issue":"227","key":"10.1016\/j.anai.2025.02.026_bib0048","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome- long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.anai.2025.02.026_bib0049","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haematopoietic stem\/progenitors cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase I\/II clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.anai.2025.02.026_bib0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2019.03.012","article-title":"Lentiviral gene therapy corrected platelet phenotype and function in patients with Wiskott-Aldrich syndrome","volume":"144","author":"Sereni","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0051","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.anai.2025.02.026_bib0052","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/blood.2022019117","article-title":"Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","volume":"142","author":"Labrosse","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0053","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/s41467-020-17626-2","article-title":"Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich syndrome","volume":"11","author":"Rai","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101208","article-title":"Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome","volume":"32","author":"Pille","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.anai.2025.02.026_bib0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0056","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0057","article-title":"Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy","volume":"4","author":"Sobrino","year":"2023","journal-title":"Cell Reprod Med"},{"issue":"9","key":"10.1016\/j.anai.2025.02.026_bib0058","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.2022016074","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression","volume":"141","author":"Wong","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.anai.2025.02.026_bib0059","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008503","article-title":"Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem\/progenitor cells","volume":"137","author":"De Ravin","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0060","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s42003-024-06959-z","article-title":"Gene editing of NCF1 loci is associated with homologous recombination and chromosomal rearrangements","volume":"7","author":"Raimondi","year":"2024","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.anai.2025.02.026_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102229","article-title":"Targeted knock-in of NCF1 cDNA into the NCF2 locus leads to myeloid phenotypic correction of p47 phox -deficient chronic granulomatous disease","volume":"35","author":"Siow","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"23-24","key":"10.1016\/j.anai.2025.02.026_bib0062","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/hum.2022.065","article-title":"Preclinical evaluation of foamy virus vector-mediated gene addition in human hematopoietic stem\/progenitor cells for correction of leukocyte adhesion deficiency type 1","volume":"33","author":"Smith","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.anai.2025.02.026_bib0063","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omtm.2022.07.015","article-title":"Preclinical safety and efficacy of lentiviral-mediated gene therapy for leukocyte adhesion deficiency type I","volume":"26","author":"Mesa-N\u00fa\u00f1ez","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.02.026_bib0064","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1182\/blood-2022-158578","article-title":"Study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency","volume":"140","author":"Booth","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anai.2025.02.026_bib0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/crispr.2024.0006","article-title":"Comparison of gene editing approaches for severe congenital neutropenia-causing mutations in the ELANE gene","volume":"7","author":"Ritter","year":"2024","journal-title":"CRISPR J"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0066","first-page":"23","article-title":"CRISPR\/Cas9-mediated Cxcr4 disease allele inactivation for gene therapy in a mouse model of WHIM syndrome","volume":"142","author":"Gao","year":"2023","journal-title":"Blood"},{"issue":"668","key":"10.1016\/j.anai.2025.02.026_bib0067","doi-asserted-by":"crossref","first-page":"eabn5811","DOI":"10.1126\/scitranslmed.abn5811","article-title":"Therapeutic gene editing of T cells to correct CTLA-4 insufficiency","volume":"14","author":"Fox","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anai.2025.02.026_bib0068","doi-asserted-by":"crossref","first-page":"15820","DOI":"10.1038\/s41598-017-15689-8","article-title":"Ectopic FOXP3 expression preserves primitive features of human hematopoietic stem cells while impairing functional T cell differentiation","volume":"17","author":"de Sio","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0069","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2018.12.003","article-title":"Lentiviral gene therapy in HSCs restores lineage-specific Foxp3 expression and suppresses autoimmunity in a mouse model of IPEX syndrome","volume":"24","author":"Masiuk","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101183","article-title":"Efficient and sustained FOXP3 locus editing in hematopoietic stem cells as a therapeutic approach for IPEX syndrome","volume":"32","author":"Singh","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.anai.2025.02.026_bib0071","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1002\/cti2.1214","article-title":"Human-engineered Treg-like cells suppress FOXP3- deficient T cells but preserve adaptive immune responses in vivo","volume":"9","author":"Sato","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.anai.2025.02.026_bib0072","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.omtm.2021.01.007","article-title":"Effective, safe and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector","volume":"20","author":"Seymour","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0073","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/crispr.2020.0080","article-title":"Optimizing integration and expression of transgenic Bruton's tyrosine kinase for CRISPR-Cas9-mediated gene editing of X-linked agammaglobulinemia","volume":"4","author":"Gray","year":"2021","journal-title":"CRISPR J"},{"issue":"11","key":"10.1016\/j.anai.2025.02.026_bib0074","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.anai.2025.02.026_bib0075","doi-asserted-by":"crossref","first-page":"e13545","DOI":"10.15252\/emmm.202013545","article-title":"Modeling, optimization and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome","volume":"13","author":"Vavassori","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"9","key":"10.1016\/j.anai.2025.02.026_bib0076","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","article-title":"Site-specific gene editing of human hematopoietic stem cells for X-linked hyper -IgM syndrome","volume":"23","author":"Kuo","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.anai.2025.02.026_bib0077","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaci.2017.11.050","article-title":"T cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations","volume":"142","author":"Ghosh","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"11-12","key":"10.1016\/j.anai.2025.02.026_bib0078","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2019.329","article-title":"Lentiviral gene therapy for familial hemophagocytic lymphohistiocytosis type 3, caused by UNC13D gene defects","volume":"31","author":"Takushi","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0079","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaci.2023.08.003","article-title":"Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis","volume":"153","author":"Dettmer-Monaco","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.02.026_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101323","article-title":"Lentiviral vectors for precise expression to treat X-linked proliferative disease","volume":"32","author":"Ayoub","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.anai.2025.02.026_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.828489","article-title":"Genome editing with TALEN, CRISPR-Cas9 and CRISPR-Cas12a in combination with AAV homology donor restores T cell function in XLP","volume":"4","author":"Houghton","year":"2022","journal-title":"Front Genome Ed"},{"issue":"2","key":"10.1016\/j.anai.2025.02.026_bib0082","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10875-022-01389-0","article-title":"Lentiviral gene transfer corrects immune abnormalities in XIAP deficiency","volume":"43","author":"Topal","year":"2023","journal-title":"J Clin Immunol"},{"issue":"26","key":"10.1016\/j.anai.2025.02.026_bib0083","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.2021011192","article-title":"CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes","volume":"138","author":"Brault","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.anai.2025.02.026_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101133","article-title":"Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction","volume":"31","author":"Poggi","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.anai.2025.02.026_bib0085","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun"},{"issue":"6708","key":"10.1016\/j.anai.2025.02.026_bib0086","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.ads0252","article-title":"Cell and gene therapy accessibility","volume":"385","author":"Rouce","year":"2024","journal-title":"Science"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625001176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625001176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:15:29Z","timestamp":1748855729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1081120625001176"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.02.026","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for inborn errors of immunity","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}